AstraZeneca, Eolas in $145m deal for anti-smoking drug
This article was originally published in Scrip
Carlsbad, California-based private biotechnology firm Eolas Therapeutics could earn up to $145m in upfront, clinical and regulatory milestone fees plus royalties from AstraZeneca under an agreement to develop an orexin-1 receptor antagonist (EORA) for smoking cessation and other indications.
You may also be interested in...
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.